Lumida
/ARWR
⌘K
Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals Inc

ARWR
$86.73USD-0.44%-0.38 today

MARKET CAP

12.3B

P/E (TTM)

FWD P/E

DAY RANGE

$86 – $87

52W RANGE

$20
$95

AI Summary

Stalk
StalkMedium

ARWR has delivered a clear momentum breakout above the ~77 resistance on heavy volume, signaling a new expansionary phase, but price is currently stretched above rising EMAs and in extreme overbought territory. Medium-term bias remains bullish in Stage 2 with HH/HL structure intact. Execution is best deferred until a pullback into the 77–79 support zone near the 9/20 EMAs for better risk–reward.

  • Q3 revenue $75.3M beat forecasts; net loss was $194.3M
  • Phase 3 SHASTA-3/4 trials achieved 79–81% triglyceride cuts, fewer pancreatitis events
  • Q3 net loss $194.3M and EPS $1.36 miss underscore high expenses
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$138.3M$243.2M$240.7M$3.6M$829.4M
YoY %+57.2%+75.9%-1.0%-98.5%+23258.2%
P / Sales46.8x14.3x11.6x653.4x5.6x
EV / Sales47.7x15.0x13.2x891.7x6.4x
Gross Profit, Adj.$138.3M$243.2M$240.7M$3.6M$829.4M
YoY %+57.2%+75.9%-1.0%-98.5%+23258.2%
Margin %100.0%100.0%100.0%100.0%100.0%
EV / Gross Profit47.7x15.0x13.2x891.7x6.4x
EBITDA, Adj.$-140.8M$-168.1M$-192.5M$-582.5M$122.3M
YoY %-61.4%-19.4%-14.5%-202.6%+121.0%
Margin %-101.8%-69.1%-80.0%-16403.4%14.7%
EV / EBITDA-46.8x-21.7x-16.5x-5.4x43.1x
EBIT$-149.0M$-178.5M$-205.0M$-601.1M$98.3M
YoY %-60.0%-19.8%-14.8%-193.2%+116.4%
Margin %-107.8%-73.4%-85.2%-16927.1%11.9%
EV / EBIT-44.2x-20.4x-15.5x-5.3x53.6x
Net Income$-140.8M$-176.1M$-205.3M$-599.5M$-1.6M
YoY %-66.6%-25.0%-16.6%-192.0%+99.7%
Net Margin-101.9%-72.4%-85.3%-16882.4%-0.2%
EPS (GAAP)-$1.36-$1.67-$1.92-$5.00-$0.01
YoY %-61.9%-22.8%-15.0%-160.4%+99.8%